Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: The 'OPTIMIZE-IT' pilot randomized study

Journal of Cardiovascular Medicine

Volumn 10, Issue 3, 2009, Pages 245-251

  Talarico, Giovanni Paolo ^a   Brancati, Marta ^a   Burzotta, Francesco ^a,b   Porto, Italo ^a   Trani, Carlo ^a   De Vita, Maria ^a   Todaro, Daniel ^a   Giammarinaro, Maura ^a   Leone, Antonio Maria ^a   Niccoli, Giampaolo ^a   Andreotti, Felicita ^a   Mazzari, Mario Attilio ^a   Schiavoni, Giovanni ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NONE   (Italy)

Author keywords

Diabetes mellitus; IIb IIIa inhibitors; Percutaneous coronary interventions

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; INSULIN; PLACEBO; TICLOPIDINE; TIROFIBAN; TROPONIN T; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; TYROSINE;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; ARTIFICIAL EMBOLISM; BARE METAL STENT; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CHECKLIST; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG ELUTING STENT; DRUG MEGADOSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; LABORATORY TEST; MALE; MUSCLE NECROSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; POSTOPERATIVE COMPLICATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SCREENING; SMOKING; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; BLOOD; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; HEART MUSCLE; INSTRUMENTATION; MIDDLE AGED; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RADIOGRAPHY; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NECROSIS; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; STENTS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T; TYROSINE;

EID: 63049096681     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32832180d9     Document Type: Article

References (19)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234. (Pubitemid 28350165)
2. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91:979-989.
3. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996; 94:1818-1825.
4. Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997; 96:2551-2556. (Pubitemid 27451345)
5. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96:1761-1769.
6. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35:922-928. (Pubitemid 30189923)
7. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004; 44:14-19. (Pubitemid 38968448)
8. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath, ISARSWEET Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110:3627-3635.
9. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006; 48:1-11. (Pubitemid 44202476)
10. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007; 116:2634-2653.
11. Sestito A, Sciahbasi A, Landolfi R, Maseri A, Lanza GA, Andreotti F. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA- 100): reproducibility and effects of sex and age. Cardiologia 1999; 44:661-665.
12. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93:879-888.
13. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998; 97:2302-2306.
14. Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002; 40:662-668. (Pubitemid 34925612)
15. The Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28:1598-1660.
16. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, The Task Force on the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24:28-66.
17. ESPRIT Investigator (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy). Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebocontrolled trial. Lancet 2000; 356:2037-2044.
18. Roffi M, Moliterno DJ, Meir B, et al. Impact of different platelet glycoprotein Iib/IIIa receptor inhibitors among diabetic patients undergoing percutaneuos coronary intervention: do Tirofiban And ReoPro Give similar Efficacy outcomes Trial (TARGET) 1-year follow-up. Circulation 2002; 105:2730-2736. (Pubitemid 34615143)
19. Gibson CM, Dotani MI, Murphy SA, Marble SJ, Dauterman KW, Michaels AD, Dodge JT Jr. RESTORE Investigators. Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Am Heart J 2002; 144:130-135.